Pfizer received approval from the European Commission (EC) for Celsentri (maraviroc) for treatment-experienced HIV patients. Maraviroc, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 virus detectable. Maraviroc is the first of a new class of oral HIV medicines that works by blocking viral entry into human cells rather than fighting HIV inside white blood cells. Maraviroc prevents the vir...